Company profile
The Vaccine Group - developing herpesvirus based animal vaccines
TVG is using recombinant viral vector technology to develop a pipeline of new animal vaccines to tackle zoonotic and economically damaging diseases.
Updated 06 Jun 2026 16:52
Financial period: 1 Jul 2024 to 30 Jun 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
MA | Transaction MzUxMjI3Mzc1NmFkaXF6a2N4 | Paper/PDF filed
Published 04 Apr 2026 05:39
RESOLUTIONS | Transaction WUVZSUdGN0xhZGlxemtjeA | Paper/PDF filed
Published 04 Apr 2026 05:38
CC04 | Transaction MzUxMjI3MzM5MGFkaXF6a2N4 | Paper/PDF filed
Published 04 Apr 2026 05:38
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0NDA4NDA5MmFkaXF6a2N4
Published 19 Nov 2024 09:33
Company registered at Companies House
1 Sep 2024 to 31 Mar 2026
TVG, a UK-based biotech SME, is collaborating with The Animal and Plant Health Agency (APHA) on this project. The core project team comprises Claudio Busato (project lead, APHA), Jeremy Salt (CEO, TVG) and Michael Jarvis (CSO, TVG). Livestock production is a vital source of nutrition for the growing worldwide population. Infectious diseases in livestock h...
1 Jun 2024 to 31 May 2026
_Streptococcus suis_(_S.suis_) is a bacterial pathogen that can cause serious and often fatal disease in pigs and humans. This poses a challenge to the pork industry and public health. It costs pig farmers thousands of pounds each year in losses and treatments. There are no commercial vaccines available in the UK, and the _S.suis_ vaccines used in other c...
1 Apr 2019 to 30 Sep 2022
Vaccines are one of medicine's greatest triumphs, having led to the virtual eradication of several deadly bacterial diseases. However, most vaccines in use today were developed by techniques pioneered over 100 years ago and do not represent the full potential of the field. Bovine herpes virus vaccines (BoHV-4) are one of the most promising classes of new ...
